Angiotech Pharmaceuticals Sells Interventional Products Business

Print PDF
April 2013

Irell & Manella LLP represented Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company, in connection with the $362.5 million sale of its interventional products business to Argon Medical Devices, Inc. The transaction closed on April 12, 2013.

The core deal team included Gregory Klein, Elliot Freier and Michael Kaplan. Gary Frischling, Sandra Kanengiser, Kimberly Bick, Charles Elder and Mitchell Cohen also worked on the deal.

Irell & Manella previously represented Angiotech Pharmaceuticals in connection with the sale of its Quill™ knotless tissue closure product line to Ethicon, a subsidiary of Johnson & Johnson, for a purchase price that could reach $62 million.